The latest developments in advanced therapies, gene editing, virtual and adaptive clinical trials, integrated care solutions, affordability and access to medicines have profoundly transformed development programs and the patient journey.
But the industry has also faced an array of challenges in recent years. The belief that companies have a responsibility to serve the broader community as much as their own shareholders is fast becoming the accepted norm.